Seagen Inc.
CD47 Antibodies and Uses Thereof for Treating Cancer

Last updated:

Abstract:

Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.

Status:
Application
Type:

Utility

Filling date:

20 Oct 2021

Issue date:

5 May 2022